Psychedelic and ketamine research trials in Norway
Curated snapshot as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.
This is a dated selection from the broader clinical catalogue for Norway, not a complete inventory of research. The catalogue loads separately, may show cached records, and includes compounds and ketamine uses outside this hub's scope. Scope and update timing can produce different totals. Historical publications are separate from these registered-study counts.
4 registered studies are counted in Norway. By compound: 1 MDMA and 3 ketamine. By registry status: 1 recruiting, 2 completed and 1 terminated. By phase: 1 phase 1, 1 phase 2, 1 phase 3 and 1 phase 4. Reported start years run from 2009 (earliest) to 2025 (latest). Studies are linked to 6 source-listed facility records.
Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Facility records may include aliases or departments of the same institution; they are not a count of unique institutions. A listed facility does not establish a sponsor, lead site or care provider role, or confirm recruitment.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting or not yet recruiting
1 of the 4 counted studies is listed in the registry as recruiting (1) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Registry dates | Source-listed facility and city |
|---|---|---|---|---|---|
| Ketamine for Combined Depression and Alcohol Use Disorder | NCT06090422 | Recruiting | Phase 1 | Source start: 2025-01-20 (actual) Saved start 2025-01-01 differs from reported 2025-01-20; the saved day is not established by this observation. Source date detailsStart: 2025-01-20 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-07-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-07-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2026-06-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Department of Addiction, University Hospital of North Norway, Tromsø |
At a glance
- 4 registered studies are counted on this page.
By compound
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 25% |
| Completed | 2 | 50% |
| Terminated | 1 | 25% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 25% |
| Phase 2 | 1 | 25% |
| Phase 3 | 1 | 25% |
| Phase 4 | 1 | 25% |
Registry-listed start years
| Start year | Studies |
|---|---|
| 2024 and later | 1 |
| 2020 to 2023 | 2 |
| Before 2010 | 1 |
All counted studies
All 4 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Source-listed facility and city |
|---|---|---|---|---|---|
| Ketamine for Combined Depression and Alcohol Use Disorder | NCT06090422 | Recruiting | Phase 1 | Source start: 2025-01-20 (actual) Saved start 2025-01-01 differs from reported 2025-01-20; the saved day is not established by this observation. Source date detailsStart: 2025-01-20 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-07-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-07-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2026-06-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Department of Addiction, University Hospital of North Norway, Tromsø |
| A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder | NCT04338321 | Completed | Phase 3 | Source start: 2020-08-21 (actual)Source date detailsStart: 2020-08-21 (precision: day; source type: ACTUAL; actual) Primary completion: 2022-01-20 (precision: day; source type: ACTUAL; actual) Study completion: 2022-07-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.343Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | St Olav University Hospital, Trondheim; Haukeland University Hospital, Hordaland; Sykehuset Ostfold, Moss |
| Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | NCT04030169 | Completed | Phase 2 | Source start: 2020-06-24 (actual)Source date detailsStart: 2020-06-24 (precision: day; source type: ACTUAL; actual) Primary completion: 2023-12-14 (precision: day; source type: ACTUAL; actual) Study completion: 2023-12-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.077Z; registry revision: 2025-01-28 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Sykehuset Østfold Hf, DPS Norder, Moss |
| Reversal of Ketamine Pharmacodynamic Effects With Naloxone | NCT00921765 | Terminated | Phase 4 | Source start: 2009-12 (type unknown) Saved start 2009-12-01 and reported 2009-12 have different precision. Source date detailsStart: 2009-12 (precision: month; source type: not reported; unknown) Primary completion: 2017-12 (precision: month; source type: ACTUAL; actual) Study completion: 2017-12 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.748Z; registry revision: 2018-04-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ullevaal University Hospital, Oslo |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 2 |
| Alcohol use disorder | 1 |
| Post-traumatic stress disorder | 1 |
| Treatment-resistant depression | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Germany | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Turkey | Greece | Hungary | Italy | Mexico | Bulgaria | Egypt | Pakistan | Portugal